Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | PRNP | P04156 | 1/20 | 0.56 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 3/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819403 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL30475131 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL3958079 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL8012040 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL5360209 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL18815844 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL27081326 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL629696 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2PRNPMETAP1MALT1CA1 | |
| SCHEMBL3045910 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2PRNPCA1CA2 | |
| SCHEMBL6795634 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2PRNPMETAP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970156-B1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2970156-B1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2970156-A2 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2014144545-A2 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-1757599-A1 | INDOLE DERIVATIVES HAVING PIPERIDINE RINGS | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757599-A1 | INDOLE DERIVATIVES HAVING PIPERIDINE RINGS | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000337-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000340-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| US-20050256103-A1 | Indole derivative having piperidine ring | EISAI CO., LTD. | 2005-11-17 | — | — | US | disclosed |
| US-5272170-A | Tetralones with pharmacological activity | J. URIACH & CIA., S.A. (ES) | 1993-12-21 | — | — | US | disclosed |
| US-5208246-A | Hypotensive, bronchodilator | J. URIACH & CIA. (ES) | 1993-05-04 | — | — | US | disclosed |
| EP-0489300-A2 | Tetralones with pharmacological activity | J. URIACH & CIA. S.A. (ES) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | CYP4X1, BRIX1, HAX1 | SMN1; SMN2 2512/4885PRNP 1461/4885METAP1 3121/4885 |
| US-20050256103-A1 | Indole derivative having piperidine ring | HTR5A, HTR2C, HTR1A | SMN1; SMN2 3116/4885PRNP 3416/4885METAP1 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.